| George William Croft Stone, MD | |
|
745 Poplar Road, Newnan, GA 32605-1618 | |
| (770) 400-1000 | |
| (803) 434-4419 |
| Full Name | George William Croft Stone |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 18 Years |
| Location | 745 Poplar Road, Newnan, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295850386 | NPI | - | NPPES |
| 003109562M | Medicaid | GA | |
| P01060229 | Other | GA | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 29055 (South Carolina) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | 059768 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Piedmont Fayette Hospital | Fayetteville, GA | Hospital |
| Piedmont Newnan Hospital, Inc | Newnan, GA | Hospital |
| Wellstar Spalding Regional Hospital | Griffin, GA | Hospital |
| Piedmont Hospital | Atlanta, GA | Hospital |
| Northside Hospital | Atlanta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Radiology And Medical Imagery Of Newnan | 5395738348 | 29 |
| Sands Imaging Associates Llc | 8527474733 | 7 |
News Archive
The irregular migrant refugees coming to European nations are often accused on bringing with them host of exotic communicable diseases that tend to spread among the host communities. The World Health Organization (WHO) this week has absolved the migrants of spreading disease in its first report that deals with this issue.
Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.
Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world's premier annual meeting for interventional cardiologists.
A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 8 days ago
| Entity Name | The Emory Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396798229 PECOS PAC ID: 8820901408 Enrollment ID: O20031110000503 |
News Archive
The irregular migrant refugees coming to European nations are often accused on bringing with them host of exotic communicable diseases that tend to spread among the host communities. The World Health Organization (WHO) this week has absolved the migrants of spreading disease in its first report that deals with this issue.
Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.
Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world's premier annual meeting for interventional cardiologists.
A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 8 days ago
| Entity Name | Emory Medical Care Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063452381 PECOS PAC ID: 4981501814 Enrollment ID: O20031217000968 |
News Archive
The irregular migrant refugees coming to European nations are often accused on bringing with them host of exotic communicable diseases that tend to spread among the host communities. The World Health Organization (WHO) this week has absolved the migrants of spreading disease in its first report that deals with this issue.
Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.
Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world's premier annual meeting for interventional cardiologists.
A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 8 days ago
| Entity Name | Piedmont Providers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548273592 PECOS PAC ID: 9830082825 Enrollment ID: O20040204000321 |
News Archive
The irregular migrant refugees coming to European nations are often accused on bringing with them host of exotic communicable diseases that tend to spread among the host communities. The World Health Organization (WHO) this week has absolved the migrants of spreading disease in its first report that deals with this issue.
Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.
Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world's premier annual meeting for interventional cardiologists.
A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 8 days ago
| Entity Name | Radiology & Medical Imagery Of Newnan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447268842 PECOS PAC ID: 5395738348 Enrollment ID: O20040406000256 |
News Archive
The irregular migrant refugees coming to European nations are often accused on bringing with them host of exotic communicable diseases that tend to spread among the host communities. The World Health Organization (WHO) this week has absolved the migrants of spreading disease in its first report that deals with this issue.
Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.
Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world's premier annual meeting for interventional cardiologists.
A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 8 days ago
| Entity Name | Department Of Behavioral Health And Developmental Disabilities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902030307 PECOS PAC ID: 7416002506 Enrollment ID: O20090825000435 |
News Archive
The irregular migrant refugees coming to European nations are often accused on bringing with them host of exotic communicable diseases that tend to spread among the host communities. The World Health Organization (WHO) this week has absolved the migrants of spreading disease in its first report that deals with this issue.
Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.
Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world's premier annual meeting for interventional cardiologists.
A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 8 days ago
| Entity Name | Georgia Radiology Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124256540 PECOS PAC ID: 6901028174 Enrollment ID: O20141104001866 |
News Archive
The irregular migrant refugees coming to European nations are often accused on bringing with them host of exotic communicable diseases that tend to spread among the host communities. The World Health Organization (WHO) this week has absolved the migrants of spreading disease in its first report that deals with this issue.
Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.
Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world's premier annual meeting for interventional cardiologists.
A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 8 days ago
| Entity Name | S&s Imaging Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689262347 PECOS PAC ID: 8527474733 Enrollment ID: O20210315000611 |
News Archive
The irregular migrant refugees coming to European nations are often accused on bringing with them host of exotic communicable diseases that tend to spread among the host communities. The World Health Organization (WHO) this week has absolved the migrants of spreading disease in its first report that deals with this issue.
Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.
Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world's premier annual meeting for interventional cardiologists.
A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| George William Croft Stone, MD 745 Poplar Road, Newnan, GA 30265-1618 Ph: (770) 400-1000 | George William Croft Stone, MD 745 Poplar Road, Newnan, GA 32605-1618 Ph: (770) 400-1000 |
News Archive
The irregular migrant refugees coming to European nations are often accused on bringing with them host of exotic communicable diseases that tend to spread among the host communities. The World Health Organization (WHO) this week has absolved the migrants of spreading disease in its first report that deals with this issue.
Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.
Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world's premier annual meeting for interventional cardiologists.
A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders.
Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.
› Verified 8 days ago
Henry J Krebs Iii, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 600 Celebrate Life Pkwy, Cancer Treatment Centers Of America, Newnan, GA 30265 Phone: 770-400-6008 Fax: 404-355-6959 | |
Dr. Daniel Scott Faith, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 745 Poplar Road, Newnan, GA 32605 Phone: 770-400-1000 | |
Kent B Remley, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1665 Highway 34 E, Suite 100, Newnan, GA 30265 Phone: 770-252-7557 Fax: 770-252-7513 | |
Lillian Shakibnia, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 600 Celebrate Life Pkwy, Radiation Oncology Department, Newnan, GA 30265 Phone: 770-400-6000 | |
John R Mcnair Jr., MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 745 Poplar Road, Newnan, GA 32605 Phone: 770-400-1000 | |
Dr. Brannan Howard Hatfield, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 745 Poplar Road, Newnan, GA 32605 Phone: 770-400-1000 Fax: 404-686-5701 | |
Dr. William T Bottoms Jr., MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 745 Poplar Road, Newnan, GA 32605 Phone: 770-400-1000 |